GS-9451

DRUG6 trials

Sponsors

Gilead Sciences, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Chronic Hepatitis CHepatitis C, Chronic

Phase 2

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

CompletedNCT01271790

Gilead SciencesHepatitis C, Chronic

Start: 2010-10-31End: 2013-09-30Updated: 2014-02-06

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

CompletedNCT01353248

Gilead SciencesHepatitis C, Chronic

Start: 2011-05-31End: 2013-03-31Updated: 2013-12-20

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

CompletedNCT01356160

Gilead SciencesHepatitis C, Chronic

Start: 2011-07-31End: 2013-06-30Updated: 2014-02-03

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

TerminatedNCT01384383

Gilead SciencesChronic Hepatitis C

Start: 2011-08-31End: 2013-06-30Updated: 2014-02-03

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

CompletedNCT01435226

Gilead SciencesHepatitis C, Chronic

Start: 2011-09-30End: 2013-07-31Updated: 2013-12-17

Combination Therapy for Chronic Hepatitis C Infection

CompletedNCT01805882

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis C, Chronic

Start: 2013-01-31End: 2015-08-31Updated: 2017-06-08

Related Papers

Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.

2016-01-0121 citations

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

2015-11-2451 citations

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens

Clinical Infectious Diseases2015-10-3151 citations

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

2015-07-14109 citations

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

2015-01-13120 citations

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

2014-11-0151 citations